Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Vose

Showing results (121-130 of 299) with videos related to

Pageof 30
Sort By:
American Journal of Hematology|March 30, 2005
Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantationSteven Z Pavletic, Lynette M Smith, Michael R Bishop, et al.
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
British Journal of Haematology|April 27, 2013
CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphomaZdravko Mitrovic, Javeed Iqbal, Kai Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
International Immunopharmacology|June 16, 2007
Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell productsRakesh K Singh, Michelle L Varney, Cheryl Leutzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2003
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow TransplantationPhilip J Bierman, John W Sweetenham, Fausto R Loberiza, et al.
Leukemia & Lymphoma|September 18, 2015
Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group ExperienceVijaya R Bhatt, Fausto R Loberiza, Lynette M Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimenColin D Weekes, Julie M Vose, Jim C Lynch, et al.
American Journal of Clinical Oncology|November 7, 2013
Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapyMatthew A Lunning, Shelby Kutty, Eric T Rome, et al.
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Pageof 30

Showing results (121-130 of 299) with videos related to

Sort By:
Pageof 30
American Journal of Hematology|March 30, 2005
Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantationSteven Z Pavletic, Lynette M Smith, Michael R Bishop, et al.
British Journal of Haematology|July 10, 2013
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantationJulie M Vose, Thomas M Habermann, Myron S Czuczman, et al.
British Journal of Haematology|April 27, 2013
CD43 expression is associated with inferior survival in the non-germinal centre B-cell subgroup of diffuse large B-cell lymphomaZdravko Mitrovic, Javeed Iqbal, Kai Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
International Immunopharmacology|June 16, 2007
Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell productsRakesh K Singh, Michelle L Varney, Cheryl Leutzinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2003
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow TransplantationPhilip J Bierman, John W Sweetenham, Fausto R Loberiza, et al.
Leukemia & Lymphoma|September 18, 2015
Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group ExperienceVijaya R Bhatt, Fausto R Loberiza, Lynette M Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimenColin D Weekes, Julie M Vose, Jim C Lynch, et al.
American Journal of Clinical Oncology|November 7, 2013
Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapyMatthew A Lunning, Shelby Kutty, Eric T Rome, et al.
Leukemia Research|May 4, 2004
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphomaFrancis J Giles, Julie M Vose, Kim-Anh Do, et al.
Pageof 30